

Ref: MHL/Sec&Legal/2025-26/01

April 05, 2025

To,  
**BSE Limited**  
Scrip Code: 542650

**National Stock Exchange of India Ltd.**  
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Code of Fair Disclosure of Unpublished Price Sensitive Information & Policy for Legitimate Purpose in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has provided a business update for the quarter ended March 31, 2025.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended March 31, 2025. A detailed information update will follow once the Board of Directors approves the financial results for Q4FY25.

In Quarter 4 of this year, the healthcare industry faced weaker-than-usual performance across multiple sectors. The acute testing segment experienced a slowdown due to changes in weather conditions, resulting in reduced outpatient visits resulting in lower patient volumes. Additionally, lower elective procedures in major metropolitan hospitals affected our specialty testing business. The industry's challenges led to a subdued quarter, impacting both quarterly and annual performance.

Despite these industry-wide challenges, the company achieved double-digit revenue growth in Q4FY25. While the acute care segment experienced a slowdown, the wellness segment continued to show robust growth.

**Please find below the key highlights of Q4FY25:**

1. Revenues grew by approx. **10%** on a Y-o-Y basis. Revenue growth was driven by patient volume growth, test volume growth and change in product mix coupled with realization benefits.
2. B2C revenues grew at approx. **14%** on a Y-o-Y basis on account of consumer experience and expansion of service network.
3. Operational EBITDA for the current quarter has grown marginally lower due to higher material costs and reduced revenue growth. Reported EBIDTA is lower due to one-time costs including acquisition costs for Core Diagnostics & Scientific Pathology and lower margin from Core Diagnostics.
4. The Company is debt free & has cash reserves of approx. **INR 112 crores** post paying towards acquisition amounting to INR 130 crores as on March 31, 2025.

The quarterly business update is on a consolidated basis including financial of Core Diagnostics for 11 days of operations post-acquisition. EBIDTA for Core Diagnostics is break-even. The financial results of Q4FY25 are subject to review by Auditors.

Thanking you,  
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni  
Head – Legal & Secretarial

